AR127448A1 - Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer - Google Patents

Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer

Info

Publication number
AR127448A1
AR127448A1 ARP220102893A ARP220102893A AR127448A1 AR 127448 A1 AR127448 A1 AR 127448A1 AR P220102893 A ARP220102893 A AR P220102893A AR P220102893 A ARP220102893 A AR P220102893A AR 127448 A1 AR127448 A1 AR 127448A1
Authority
AR
Argentina
Prior art keywords
cancer
treatment
quinazolin
benzo
amine derivatives
Prior art date
Application number
ARP220102893A
Other languages
English (en)
Original Assignee
Basilea Pharmaceutica Int Ag Allschwil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Int Ag Allschwil filed Critical Basilea Pharmaceutica Int Ag Allschwil
Publication of AR127448A1 publication Critical patent/AR127448A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de fórmula (1) y sales farmacéuticamente aceptables de los mismos; en donde Rᵃ y Rᵇ son ambos -CH₃ o Rᵃ y Rᵇ juntos forman un -CH₂-CH₂-CH₂- o un resto de puenteo -CH₂-CH₂-CH₂-CH₂-; A es -CH₂- o -C(=O)-; T es -N(R¹¹)-, -N(R¹¹)-C(=O)-, -N(R¹¹)-S(O₂)-, -O-, -C(R¹²)(R¹³)-, -C=C(R¹²)₂, -S-, -S(O)-, -S(O₂)-, -S(O₂)-N(R¹⁴)- o -C(=O)-N(R¹⁴)-; y en donde R¹, R², R¹¹, R¹², R¹³ y R¹⁴ son como se definen en las reivindicaciones, así como métodos de uso de los compuestos para el tratamiento de enfermedades neoplásicas, tales como cáncer. Reivindicación 24: Una composición farmacéutica que comprende un compuesto de fórmula (1) como se ha definido en una cualquiera de las reivindicaciones 1 a 20 o una sal farmacéuticamente aceptable del mismo y opcionalmente un excipiente farmacéuticamente aceptable.
ARP220102893A 2021-10-25 2022-10-25 Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer AR127448A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204520 2021-10-25
EP22167146 2022-04-07
EP22186200 2022-07-21

Publications (1)

Publication Number Publication Date
AR127448A1 true AR127448A1 (es) 2024-01-24

Family

ID=84361577

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102893A AR127448A1 (es) 2021-10-25 2022-10-25 Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer

Country Status (3)

Country Link
AR (1) AR127448A1 (es)
TW (1) TW202334097A (es)
WO (1) WO2023072913A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR101714799B1 (ko) * 2008-12-30 2017-03-09 아르퀼 인코포레이티드 치환된 5,6-디히드로-6-페닐벤조［ｆ］이소퀴놀린-2-아민 화합물

Also Published As

Publication number Publication date
TW202334097A (zh) 2023-09-01
WO2023072913A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR100073A1 (es) Sulfonas heterocíclicas sustituidas con heteroarilos
AR097325A1 (es) Pirroles anillados
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
UY27658A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
MX2020003993A (es) Derivados de bencimidazol y sus usos.
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
AR057525A1 (es) Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR127448A1 (es) Derivados de benzo[h]quinazolin-4-amina para el tratamiento del cáncer
AR117510A1 (es) COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
ECSP20026023A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
AR088002A1 (es) Derivados de metansulfonamida sustituidos con arilo o n-heteroarilo como ligandos del receptor vanilloide
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos